EXECUTIVE SPEAKING FACULTY INCLUDES:
(Confirmed as of February 25, 2011)

Brian J. Gabrio, MSc, New Business Development Director, Inhalation and Transdermal Drug Delivery, 3M Drug Delivery Systems Kevin Taylor, Vice President Business Development, Adolor Corporation Carmine Stengone, Vice President, Corporate Development, Afraxis, Inc. Steven P. Damon, Senior Vice President, Business Development, Altea Therapeutics Corporation David Cipolla, Senior Director of Pharmaceutical Sciences, Aradigm Corporation Keith Bryant, Vice President, Arena Pharmaceuticals Court R. Turner, J.D., Venture Partner, Avalon Ventures Dr. Sándor Szalma, Senior Research Fellow, Oncology Informatics Head, Centocor R&D, Inc. Michael Shih, Senior Director, Business Development, Eisai Inc Vik Seoni, Vice President & Head of Business Development, Elan Drug Technologies John Fraher, Chief Commercial Officer, Eurand Rekha Hemrajani, VP of Business Development, Exelixis Robin Hwang, Ph.D., Consultant, ICP Consulting Corp. Bob LaPolla, Vice President, Technology Licensing, Johnson & Johnson Pharmaceuticals Group Rajendra V. Deshpande, Ph.D., Senior Director, Emerging Technologies - Corporate Office of Science and Technology, Johnson & Johnson Armen B. Shanafelt, PhD, Venture Partner, Lilly Ventures Eric B. Risser, Vice President, Business Development, MacroGenics, Inc.

Linda A. Egger, PhD, CLP™, Senior Director, Scientific Liaison External Scientific Affairs – Diabetes and Obesity Licensing, Merck & Co. Dr. Sameeh M. Salama, Senior Director, Business Development, NAEJA Pharmaceutical Inc. David Wurtman, Vice President, Corporate Development, NexBio Inc. Anne Altmeyer, Executive Director, Business Development & Licensing, Oncology, Novartis Pharmaceuticals Daisy Rivera-Muzzio, Senior Director Product Licensing, Pfizer - Established Products Business Unit. Jennifer Friel Goldstein, Director, Pfizer Venture Investments Cheni Kwok, Senior Vice President, Corporate Development, Poniard Pharmaceuticals Allen Downs, Senior Executive Director, Licensing & Business Development, Purdue Pharma Harvinder Popli, PhD, Director and Head In- Licensing, Ranbaxy Laboratories Limited Mark Benedyk, PhD, Managing Partner, Rila Partners LLC Michael D. Step, Senior VP, Corporate Development, Santarus, Inc. Gwen Melincoff, Senior Vice President of Business Development, Shire Gary C. Cupit, PharmD, CEO & Director, Somnus Therapeutics, Inc James Hattersley, Vice President, Business Development, Sun Pharmaceutical Industries, Inc. Jones W. Bryan, Ph.D., VP Business Development, Supernus Pharmaceuticals, Inc. Thomas J. Bliss, CEO, TheraKine Limited Paul Darling, Principal, ZS Associates

OVERVIEW:
With decreasing research and development productivity, continued healthcare cost limitations and the threat of generic competition, only those companies who use the strength of internal efforts combined with successful licensing strategies will remain competitive over the next five-to-ten years. Licensing plays an increasing role in the business model of today’s pharmaceutical and biotechnology companies. Licensing options allow for companies to build upon each other's strengths and for deal terms to be structured to balance assurance and reduce risk.

While the value of licensing deals has clearly risen in the last 5 years, the number of deals among the top companies has evened out. Companies are increasingly seeking out long-term, multi-product, multi-indication partnerships rather than one-off transactional deals. Using independent and impartial model inputs in the licensing valuation process limits areas of subjective disparity, and allows deal terms to be maximized for both parties. A successful deal cannot only be judged by deal terms and revenues gained from the eventual product; the quality of the relationship between licensing partners is also equally important.

TOPICS WILL INCLUDE:

• What are the best practice strategies in developing an effective win-win licensing deal?
  
• Early versus Late Stage Partnering Opportunities
  
• Role of Corporate Investors in Today’s Deals
  
• How does the licensing process differ for in-licensing and out-licensing companies?
  
• Building An Emerging Markets Strategy
  
• The Evolving Business Model of Building a Biotech
  
• What Uncertain Financial Markets Mean for Deal-Making
  
• Maximizing Your Company Value Through Non-Traditional Alliances
  
• Creatively Structuring Licensing Deals and their Terms

Click HERE to register now!